<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343155">
  <stage>Registered</stage>
  <submitdate>5/07/2011</submitdate>
  <approvaldate>6/07/2011</approvaldate>
  <actrnumber>ACTRN12611000684921</actrnumber>
  <trial_identification>
    <studytitle>INSPIRE (International trials of aspirin to prevent recurrent venous thromboembolism)</studytitle>
    <scientifictitle>A prospective combined analysis of the ASPIRE and WARFASA: multi-centre, randomised, double-blind, placebo-controlled clinical trials examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>INSPIRE</trialacronym>
    <secondaryid>ASPIRE - ACTRN012605000004662 (ANZCTR)</secondaryid>
    <secondaryid>WARFASA - NCT00222677 (ClinicalTrials.gov)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous thromboembolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The ASPIRE and WARFASA studies are international multicentre, randomised, double-blind placebo controlled clinical trials designed to examine the efficacy and safety of low dose aspirin (100mg tablet daily for a maximum of 6 years) to prevent recurrent deep venous thrombosis (DVT) or pulmonary embolism (PE) in patients with a first episide of unprovoked VTE who have completed initial treatment with heparin and warfarin.</interventions>
    <comparator>Placebo tablet, once daily</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is the composite of objectively diagnosed symptomatic VTE or fatal PE</outcome>
      <timepoint>At end of study (4 years treatment duration)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>A) The composite of symptomatic VTE, myocardial infarction, stroke, or cardiovascular death (all serious thrombotic vascular events).</outcome>
      <timepoint>At end of study (4 years treatment duration)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>B) Symptomatic VTE , myocardial infarction, stroke, all cause mortality and major bleeding (a measure of net clinical benefit).</outcome>
      <timepoint>At end of study (4 years treatment duration)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C) Major and minor bleeding
Major bleeding defined as clinically overt bleeding 
Minor bleeding defined as all other bleeding episodes not meeting the definition of major bleeding, but which lead to discontinuation of study medication</outcome>
      <timepoint>At end of study (4 years treatment duration)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>First episode of unprovoked DVT or PE-completion of initial treatment with unfractionated heparin or low-molecular-weight heparin (or effective alternative) and warfarin (recommended treatment duration 6-24 months)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy, intolerance or contraindication for aspirin
Clear indication for aspirin, clopidogrel or a conventional (COX 1/2) NSAID.
Indication for long-term anticoagulant therapy (eg prosthetic heart valve)
Life expectancy of less than 12 months
Active bleeding or at high risk of bleeding
Anticipated non-adherance to study medications
Inability to attend follow-up because of geographical inaccessibility</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>(ASPIRE) Central randomisation is via a secure web based allocation system

(WARFASA) The randomization sequence will be computer generated. Patients will be randomized according to the consecutive box number assigned to the study center.</concealment>
    <sequence>Allocation concealment is maintained via a central web based allocation system using a computer programme.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2003</anticipatedstartdate>
    <actualstartdate>1/05/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/08/2012</actualenddate>
    <samplesize>2000</samplesize>
    <actualsamplesize>1224</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney (ASPIRE)</primarysponsorname>
    <primarysponsoraddress>NHMRC Clinical Trials Centre
92  94 Parramatta Road
Camperdown
NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC (ASPIRE)</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NZ HRC (ASPIRE)</fundingname>
      <fundingaddress>PO Box 5541
Wellesley Street
Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NSW Health (ASPIRE)</fundingname>
      <fundingaddress>Locked Mail Bag 961
North Sydney NSW 2059
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer (ASPIRE and WARFASA)</fundingname>
      <fundingaddress>Bayer AG
51368 
Leverkusen
Germany</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Perugia</sponsorname>
      <sponsoraddress>Perugia, Italy</sponsoraddress>
      <sponsorcountry>Italy</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The INSPIRE study is a prospective combined analysis of 2 previously registered studies (ASPIRE and WARFASA). This study is registered before the unblinding of either dataset</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney HREC</ethicname>
      <ethicaddress>Level 6 
Jane Foss Russell Building G02
University of Sydney NSW 2006</ethicaddress>
      <ethicapprovaldate>13/12/2002</ethicapprovaldate>
      <hrec>12-2002/3551</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John Simes (Study Chair)</name>
      <address>ASPIRE Study 
NHMRC Clinical Trials Centre 
Locked Bag 77 
Camperdown 
NSW 1450</address>
      <phone>+61 2 9562 5342</phone>
      <fax>+61 2 9562 5094</fax>
      <email>aspire@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John Simes (Study Chair)</name>
      <address>ASPIRE Study 
NHMRC Clinical Trials Centre 
Locked Bag 77 
Camperdown 
NSW 1450</address>
      <phone>+61 2 9562 5342</phone>
      <fax>+61 2 9562 5094</fax>
      <email>aspire@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rebecca Mister</name>
      <address>ASPIRE Study 
NHMRC Clinical Trials Centre 
Locked Bag 77 
Camperdown 
NSW 1450</address>
      <phone>+61 2 9562 5342</phone>
      <fax>+61 2 9562 5094</fax>
      <email>aspire@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John Simes</name>
      <address>ASPIRE Study NHMRC Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 9562 5342</phone>
      <fax />
      <email>aspire@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>